Search

Your search keyword '"Vignozzi L"' showing total 543 results
Start Over Author "Vignozzi L" Language english
543 results on '"Vignozzi L"'

1. Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder

Author

Grassi G, Cecchelli C, Vignozzi L, and Pacini S

Subjects
ocd, glutamate, immune system, inflammation, probiotics, pharmacotherapy, Therapeutics. Pharmacology, RM1-950
Abstract

Giacomo Grassi, Chiara Cecchelli, Luisa Vignozzi, Silvia Pacini Neuroscience Department, Brain Center Firenze, Florence, ItalyCorrespondence: Giacomo GrassiBrain Center Firenze, Viale Belfiore 36, Florence 50144, ItalyEmail giacomograssimd@gmail.comAbstract: Treatment-resistance is a frequent condition for obsessive-compulsive disorder (OCD). Over the past decades, a lot of effort has been made to address this issue, and several augmentation strategies of serotonergic drugs have been investigated. Antidopaminergic drugs are considered the first choice as augmentation strategy for treatment-resistant OCD patients, but they seem to work only for a subset of patients, and none of them have been officially approved for OCD. Recently, the role of glutamate and inflammation in OCD pathophysiology clearly emerged, and this has led to several investigations on glutamatergic and anti-inflammatory agents. Results seem promising but still inconclusive. Probiotic interventions (considered to modulate the immune systems and the brain activity) are gaining attention in several psychiatric fields but are still at their early stages in the OCD field. Research on new treatment approaches for OCD is moving forward, and more than one hundred interventional trials are ongoing around the world. While the vast majority of these trials involve neuromodulation and psychotherapeutic approaches, only a small proportion (around 20%) involve the investigation of new pharmacological approaches (tolcapone, nabilone, psilocybin, troriluzole, nitrous oxide, rituximab, naproxen, and immunoglobulins). Here, we provide a comprehensive review of investigational and experimental drugs to treat OCD.Keywords: OCD, glutamate, immune system, inflammation, probiotics, pharmacotherapy

Published
2021

4. The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction

Author

Gacci M, Salvi M, Sebastianelli A, Vignozzi L, Corona G, McVary KT, Kaplan SA, Maggi M, Carini M, and Oelke M

Subjects
Diseases of the genitourinary system. Urology, RC870-923
Abstract

Mauro Gacci,1 Matteo Salvi,1 Arcangelo Sebastianelli,1 Linda Vignozzi,2 Giovanni Corona,3 Kevin T McVary,4 Steven A Kaplan,5 Mario Maggi,2 Marco Carini,1 Matthias Oelke6 1Department of Urology, University of Florence, Florence, 2Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, 3Endocrinology Unit, Maggiore-Bellaria Hospital, Bologna, Italy; 4Division of Urology, Department of Surgery, Southern Illinois University School of Medicine, Springfield, IL, 5Department of Urology, Weill Cornell Medical College, Cornell University, New York, NY, USA; 6Department of Urology, Hannover Medical School, Hannover, Germany Abstract: A strong and independent association between lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and erectile dysfunction (ED) has been widely evidenced in several clinical epidemiologic studies. Preclinical animal models have provided a great deal of information on potential common pathogenic mechanisms underlying these two clinical identities. Although the efficacy of the most commonly used treatments for LUTS/BPH is well defined, the negative impact of these treatments on sexual function – in particular, on ED – has triggered the search for new treatment options. In this regard, a new role for phosphodiesterase type 5 inhibitors in the treatment of LUTS/BPH and ED has been claimed. Tadalafil is one of the most extensively investigated phosphodiesterase type 5 inhibitors for this new indication. All evidence reported to date suggests that tadalafil 5 mg once daily is a safe and effective treatment option for both LUTS/BPH and ED. Keywords: phosphodiesterase type 5 inhibitor, LUTS/BPH, ED, sexual function, Cialis

Published
2013

8. The physiological sonographic features of the ovary in healthy subjects: a joint systematic review and meta-analysis by the Italian Society of Gynecology and Obstetrics (SIGO) and the Italian Society of Endocrinology (SIE)

Author

Moro, F., Scavello, I., Maseroli, E., Rastrelli, G., Baima Poma, C., Bonin, C., Dassie, F., Federici, S., Fiengo, S., Guccione, L., Villani, M., Gambineri, A., Mioni, R., Moghetti, P., Moretti, C., Persani, L., Scambia, G., Giorgino, F., and Vignozzi, L.

Published
2023
Full Text
View/download PDF

23. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE)

Author

Caprio, M., Infante, M., Moriconi, E., Armani, A., Fabbri, A., Mantovani, G., Mariani, S., Lubrano, C., Poggiogalle, E., Migliaccio, S., Donini, L. M., Basciani, S., Cignarelli, A., Conte, E., Ceccarini, G., Bogazzi, F., Cimino, L., Condorelli, R. A., La Vignera, S., Calogero, A. E., Gambineri, A., Vignozzi, L., Prodam, F., Aimaretti, G., Linsalata, G., Buralli, S., Monzani, F., Aversa, A., Vettor, R., Santini, F., Vitti, P., Gnessi, L., Pagotto, U., Giorgino, F., Colao, A., and Lenzi, A.

Published
2019
Full Text
View/download PDF

29. The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA.

Author

Cipriani, S., Maseroli, E., Ravelli, S. A., and Vignozzi, L.

Subjects
FEMALE reproductive organs, VAGINA, ANDROGENS, GENITALIA, DEHYDROEPIANDROSTERONE, GENITOURINARY diseases
Abstract

Copyright of Climacteric is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

42. Thyroid function in Klinefelter syndrome: a multicentre study from KING group

Author

Balercia, G., Bonomi, M., Giagulli, V. A., Lanfranco, F., Rochira, V., Giambersio, A., Accardo, G., Esposito, D., Allasia, S., Cangiano, B., De Vincentis, S., Condorelli, R. A., Calogero, A., Pasquali, D., Aversa, A., Corona, G., Giorgino, F., Fabbri, A., Ferlin, A., Ferrante, E., Francavilla, F., Giagulli, V., Jannini, E., Maggi, M., Pivonello, R., Pizzocaro, Anna, Radicioni, A., Vignozzi, L., Barchi, M., Cordeschi, G., D'Andrea, S., Mambro, A. D., Foresta, C., Francavilla, S., Garolla, A., Giovannini, L., Granata, A. R. M., La Vignera, S., Motta, G., Negri, L., Pelliccione, F., Persani, L., Salzano, C., Santi, D., Selice, R., Simoni, M., Tatone, C., Tirabassi, G., Tresoldi, A. S., Vicari, E., Balercia, G., Bonomi, M., Giagulli, V. A., Lanfranco, F., Rochira, V., Giambersio, A., Accardo, G., Esposito, D., Allasia, S., Cangiano, B., De Vincentis, S., Condorelli, R. A., Calogero, A., Pasquali, D., Aversa, A., Corona, G., Giorgino, F., Fabbri, A., Ferlin, A., Ferrante, E., Francavilla, F., Giagulli, V., Jannini, E., Maggi, M., Pivonello, R., Pizzocaro, A., Radicioni, A., Vignozzi, L., Barchi, M., Cordeschi, G., D'Andrea, S., Mambro, A. D., Foresta, C., Francavilla, S., Garolla, A., Giovannini, L., Granata, A. R. M., La Vignera, S., Motta, G., Negri, L., Pelliccione, F., Persani, L., Salzano, C., Santi, D., Selice, R., Simoni, M., Tatone, C., Tirabassi, G., Tresoldi, A. S., and Vicari, E.

Subjects
Adult, Male, endocrine system, Pediatrics, medicine.medical_specialty, Hashimoto’s thyroiditi, Adolescent, endocrine system diseases, Kallmann syndrome, Thyroid hormones, Endocrinology, Diabetes and Metabolism, Thyroid Gland, Hypergonadotropic hypogonadism, Thyrotropin, 030209 endocrinology & metabolism, Hashimoto Disease, Thyroid Function Tests, Thyroiditis, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Hypogonadotropic hypogonadism, medicine, Humans, Testosterone, Klinefelter syndrome, Aged, Academic Medical Centers, business.industry, Hypogonadism, Thyroid, Hashimoto’s thyroiditis, Middle Aged, Thyroid disease, medicine.disease, Thyroid diseases, medicine.anatomical_structure, Italy, Case-Control Studies, 030220 oncology & carcinogenesis, Concomitant, Female, Thyroid function, business
Abstract

Purpose: The prevalence and the etiopathogenesis of thyroid dysfunctions in Klinefelter syndrome (KS) are still unclear. The primary aim of this study was to evaluate the pathogenetic role of hypogonadism in the thyroid disorders described in KS, with the scope to distinguish between patients with KS and hypogonadism due to other causes (Kallmann syndrome, idiopathic hypogonadotropic hypogonadism, iatrogenic hypogonadism and acquired hypogonadotropic hypogonadism after surgical removal of pituitary adenomas) called non-KS. Therefore, we evaluated thyroid function in KS and in non-KS hypogonadal patients. Methods: This is a case–control multicentre study from KING group: Endocrinology clinics in university-affiliated medical centres. One hundred and seventy four KS, and sixty-two non-KS hypogonadal men were enrolled. The primary outcome was the prevalence of thyroid diseases in KS and in non-KS. Changes in hormonal parameters were evaluated. Exclusion criterion was secondary hypothyroidism. Analyses were performed using Student’s t test. Mann–Whitney test and Chi-square test. Results: FT4 was significantly lower in KS vs non-KS. KS and non-KS presented similar TSH and testosterone levels. Hashimoto’s thyroiditis (HT) was diagnosed in 7% of KS. Five KS developed hypothyroidism. The ratio FT3/FT4 was similar in both groups. TSH index was 1.9 in KS and 2.3 in non-KS. Adjustment for differences in age, sample size and concomitant disease in multivariate models did not alter the results. Conclusions: We demonstrated in KS no etiopathogenic link to hypogonadism or change in the set point of thyrotrophic control in the altered FT4 production. The prevalence of HT in KS was similar to normal male population, showing absence of increased risk of HT associated with the XXY karyotype.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results